New Life Sciences Center For Chiron
US firm Chiron officially broke ground last week for the construction of its new Life Sciences Center in Emeryville, California. The first phase of construction includes a new five-storey 268,000 square-foot R&D building to be completed in 1998. The building will house 500 researchers.
In August, 1995, the Emeryville City Council approved Chiron's proposal to build a 2.2 million square-foot premier R&D center over a 30-year period. Chiron currently employs around 1,800 people in Emeryville in about 1 million square foot of facilities around the city, which was where Chiron was founded in 1981.
William Rutter, chairman of Chiron, said: "this new research building will enable Chiron to continue its tradition for developing and introducing innovative products that control serious diseases through prevention, diagnosis, and treatment."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze